Streptomyces amphibiosporus R310-104 (ATCC53964) produced a novel antibiotic lactimidomycin which showed inhibitory activity against fungi and prolonged the survival time of mice transplanted with experimental tumors. Structural studies clarified that lactimidomycin is a new glutarimide antibiotic having a unique unsaturated 12-memberedlactone ring.
In the course of screening for new antibiotics effective against experimental tumors, we have isolated a novel antibiotic designated lactimidomycin from the culture broth of Streptomyces amphibiosporus R310-104 collected in Akita city1'2*. The antibiotic exhibited strong cytotoxicity against various tumor cells and inhibitory activity against fungi but no antibacterial activity. It demonstrated prolongation of life span in mice bearing P388 leukemia and B l 6 melanoma. The structure oflactimidomycin was determined by spectroscopic analyses and 13C-enriched biosynthetic studies to be a novel glutarimide group antibiotic having a unique 12-memberedlactone ring as a side chain.
In this paper, we describe the production, isolation, physico-chemical properties, structure determination and biological activity of lactimidomycin. Antibiotic Production A loopful mature slant culture of S. amphibiosporus R3 10-104 was inoculated into 100 ml of vegetative mediumconsisting of soluble starch (Nichiden Kagaku) 2%, Pharmamedia(Traders Protein) 1%, ZnSO4-7H2O0.003% and CaCO3 0.4% in a 500-ml Erlenmeyer flask (pH 7.0 before sterilization).
The flask was incubated at 32°C for 7 days on a rotary shaker (200rpm) and 5 ml of vegetative inoculum was added to 100ml of sterile production medium containing Protein-S (Ajinomoto Co.) 3%, glucose 3%, Pharmamedia 0.5%, yeast extract (Oriental Yeast Co.) 0.1% and CaCO3 0.3%, pH 7.0 in a 500-ml Erlenmeyer flask. The flask was incubated at 28°C on a rotary shaker (200rpm). Antibiotic production was monitored by the in vitro cytotoxicity against B16 melanomacells and it reached maximumafter 4 days incubation.
Isolation and Purification
The fermentation broth (18 liters, pH 7.4) was stirred with 1-butanol for one hour. The solvent layer was separated from the aqueous layer and mycelial cake by use ofa Sharpies type centrifuge and concentrated under reduced pressure. The residue (30 g) was suspended in water (1 liter) and extracted three times with Lactimidomycin was originally called as BU-4146T or BMY-28886.
1 liter each of ethyl acetate. The combined organic extracts were concentrated to brown oil which was added dropwise into 600ml of «-hexane to precipitate a crude antibiotic solid (2.65 g). It was applied on a column of silica gel (Wako gel C-200, 2.0 i.d.x50cm), which was developed with methylene chloride-methanol mixture (100 : 0^90 : 10). The eluate was monitored by antifungal activity against Cryptococcus neoformans IAM45 14 using paper disc assay and also by cytotoxicity against B16 melanoma cells. The active fractions were combined and evaporated in vacuo to yield a pale yellow solid which was chromatographed on a column of silica gel (2.0 i.d. x 35 cm) pre-equilibrated with ethyl acetate -rc-hexane (1 : 1). The elution was performed with the same solvent and the bioactive fractions were pooled and concentrated to dryness. The solid obtained was further purified on Sephadex LH-20 chromatography (2.2 i.d. x 60cm) developing with methanol. The appropriate fractions were combined and concentrated in vacuo to yield a pure solid of lactimidomycin (45mg).
Physico-chemical Properties
Lactimidomycin was isolated as a pale yellow solid. It is readily soluble in lower alcohols, acetonitrile, ethyl acetate, chloroform and dimethyl sulfoxide, but practically insoluble in n-hexane and water. It gave positive responses to iodine vapor and ammonium molybdate-sulfuric acid, but negative responses to ninhydrin and anthrone reagents. The physico-chemical properties of lactimidomycin are summarized in Table 1 . Its molecular formula was determined to be C26H35NO6on the basis of microanalysis and mass spectrum (m/z 458 (M +H)+). It showed only end absorption in the UV spectrum. The IR spectrum in KBr (Fig. 1) showed strong absorption at 3230 and 1700 cm" 1 suggesting the presence ofimide group. The XHNMRspectrum is shown inFig.2.
Structure Determination
The strong absorption at 1700 cm" 1 in the IR spectrum suggested the presence of 6-memberedimide ring in lactimidomycin. The FAB-MSspectrum exhibited the pseudomolecular ion peaks at m/z 458 (M + H)+ and 480 (M +Na)+ along with strong fragment ion peaks at m/z 180 and 198 which are commonly observed for the glutarimide group antibiotics.
The XH NMRspectrum in DMSO-J6( The correlation of the protons and carbons was established as shown in Table 2 by 1H-13CCOSY spectrum. This combined with^^H COSYspectral analyses allowed us to assign three partial structures, a'b Assignments may be interchanged.
A, B and C of lactimidomycin as illustrated in Fig. 3 . The geometrical configurations of C moiety were determined to be 15Z, HE and 2\E by coupling constants of olefinic protons (/15_16=10.9Hz, j17_18=15.7Hz, J21_22=16.1Hz) and that of B moiety to be HE by NOE observed between 10-H (3 3.42) and 24, 25-H (3 1.04 and 1.72) in NOESYspectrum. In order to clarify the sequences of the three partial structures in lactimidomycin, XH-13Clong range COSYspectra were measured and analyzed (Fig. 3) . Clear correlation was observed from two methylene protons (2-H, 4-H) to imide carbonyl (C-l, C-5) and a methine carbon (C-3) establishing a glutarimidylhydroxyethyl group which is the commonfunctional group of glutarimide antibiotics. Three methyl protons displayed contour with following their relevant carbons, 24H (C-9, C-10 and C-l l), 25H (C-ll, C-12 and C-13) and 26H (C-13, C-14 and C-15) to clarify connectivities from Cl to C22. The two methine protons (13-H, 3 5.24 and 22-H, 3 5.51) showed correlation with the ester carbonyl carbon (C-23, and 308 (265 -CH2CO)supporting the assigned structure.
Biosynthetic Study
The incorporation of 13C-labeled precursors into lactimidomycin was studied to confirm the proposed structure and to clarify the biosynthetic pathway of this antibiotic.
S. amphibiosporus R3 10-104 was fermented in the presence of sodium (Table 3) supporting the assigned structure of lactimidomycin. Antimicrobial Activity The minimum inhibitory concentrations (MIC's) were determined against various bacteria and fungi by the serial agar dilution method. Nutrient agar (Eiken) was used for bacteria and Sabouraud dextrose agar (Difco) for fungi. The inoculum size was adjusted to 102~104cfu/ml for bacteria and 103 cfu/ml for activity against Gram-positive and Gram-negative bacteria at 100/ig/ml. As summarized in Table 4 , it exhibited potent activity against Cryptococcus neoformans, Aspergillus fumigatus, Fusarium rnoniliforme and Mucor spinosus, and practically no activity against Candida albicans and Trichophyton mentagrophytes. As a whole, the antifungal activity of lactimidomycin was 30~100 times more potent than that of streptimidone.
Antitumor Activity
Lactimidomycin and its hexahydro derivative were tested for their in vitro cytotoxicity and inhibition ofmacromolecule synthesis by the method described in the previous paper4). Mitomycin C and streptimidone were used as reference compounds and the results are summarized in Table 5 . Lactimidomycin showed potent cytotoxicity with the potency approximately 50~4,000 times greater than that of streptimidone and 20~600 times superior to mitomycin C in terms of IC50 value. Hexahydrolactimidomycin was significantly less active than lactimidomycin. Lactimidomycin inhibited both DNAand protein syntheses at the same extent and the IC50 values were 200 times smaller than that of RNAsynthesis. The in vivo antitumor activity was determined in the experimental mouse tumor systems. Female CDFXmice and male BDFi mice were intraperitoneally inoculated with 0.4ml of diluted ascitic fluid a % T/C: The median survival time (MST) of treatment mice/MST of control mice, x 100. Significant activity was considered to be a T/C of > 125% in each tumor model evaluated.
ND: Not determined.
containing 106 lymphocytic leukemia P388 cells and 0.5ml of 10% melanotic melanoma B16 brei, respectively. Test compoundswere administered to the mice intraperitoneally once a day on days 1, 5 and 9 (Q4D x 3) and once daily on days 1 to 9 (QID x 9). Lactimidomycin demonstrated fairly good anti-P388 leukemic activity by Q1Dx 9 treatment with the potency being comparable to that of mitomycin C, while it gave moderate antitumor activity against B 1 6 melanoma (Table 6 ). Streptimidone showed no prolongation of life span of P388 leukemia-bearing mice. Although in vivo toxicity have not been tested, lactimidomycin was lethal at 32mg/kg (01D x 3, ip) in tumor-bearing mice.
Discussion
Lactimidomycin, a novel glutarimide antibiotic having a unique 1 2-memberedlactone ring, was isolated from the fermentation broth of S. amphibiosporus. It showed potent antifungal activity, cytotoxicity and in vivo antitumor activity in mice. Among the glutarimide class antibiotics, streptimidone5>6), 9-methylstreptimidone7), protomycin8) and S-632 Bl9 B29'10) have an acyclic unsaturated ketone side chain. However, none of this class antibiotic contains an unsaturated lactone side chain. Moreover, lactimidomycin is differentiated from the other known glutarimide antibiotics by its potent antitumor activity. Whenthe lactone ring was saturated by hydrogenation, the resulting hexahydro derivative exhibited only weak antifungal activity and cytotoxicity. This indicated that the unsaturated 12-membered lactone in lactimidomycin plays an important role for its distinct biological activity.
Experimental
General TLC was performed on precoated silica gel plates (Kieselgel 60F254). IR spectra were recorded on a Jasco IR-810 and UVspectra on a UVIDEC-610Cspectrometer. XH and 13C NMRspectra were measured on a Jeol JNM-GX400 spectrometer operated in Fourier transform mode. EI-MS were obtained on a Hitachi M80Band FAB-MSon a Jeol JMS-AX505H using m-nitrobenzyl alcohol as the matrix. Optical rotations were determined with a Jasco model DIP 140. 3H, d, 7.2), 1.00 (3H, d, 6.8), 1.10 (1H, m), 1.2 (m), 1.58 (1H, m), 1.64 (1H, m), 1.67  (3H, d, 1.3), 1.78 (1H, m), 1.87 (1H, m) Feeding Experiment with 1 3C-enriched Precursors Strain R310-104 was grown at 32°C for 5 days in a 100ml ofvegetative medium composed of soluble starch 2%, Pharmamedia 1 %, ZnSO4 0.003% and CaCO30.4%, pH 7.0 in a 500-ml Erlenmeyer flask and aliquot (5ml) was transferred to a 100ml of production medium containing glucose 3%, Protein S 3%, ]-L-methionine (99 atom%13C, Aldrich Chemical Co.) were disolved in distilled water at the concentration of 160 mg/ml, lOOmg/ml and 30mg/ml, respectively, and sterilized by filtration. In all cases, l ml aliquot each of the labeled precursor solution was fed to 100ml of the growing cultures at 40, 52 and 64 hours after inoculation. The fermentation was continued 24 hours after final addition of the labeled precursor. The 13C-labeled lactimidomycin was extracted from the fermentation broth (1.0 liter) with 1 -butanol and purified using solvent partition follow by successive chromatographies on silica gel and Sephadex LH-20 to yield a sample (3 -6mg) for 13C NMRspectroscopic analysis.
